ArticleToxicology research2016

Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi.

Vilmos Csizmadia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.